MoonLake Immunotherapeutics (MLTX)
$15.11
$-0.43
(-2.74%)
As on 28-Aug-2026 13:39EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MoonLake Immunotherapeutics (MLTX)
| 14.6 | -24.0 | -18.0 | -72.7 | -35.7 | 8.9 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
MoonLake Immunotherapeutics (MLTX)
| -75.7 | -10.3 | 475.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of... inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Read more
-
Co-Founder, CEO & Director
Dr. Jorge Santos da Silva
-
Co-Founder, CEO & Director
Dr. Jorge Santos da Silva
-
Headquarters
Zug
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MoonLake Immunotherapeutics (MLTX)
What is the current share price of MoonLake Immunotherapeutics (MLTX) Today?
The share price of MoonLake Immunotherapeutics (MLTX) is $15.11 (NASDAQ) as of 28-Aug-2026 13:39 EDT. MoonLake Immunotherapeutics (MLTX) has given a return of -35.7% in the last 3 years.
What is the current PB & PE ratio of MoonLake Immunotherapeutics (MLTX)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.74 |
2.79 |
2024 |
-28.71 |
7.64 |
2023 |
-100.49 |
7.30 |
2022 |
-6.32 |
8.34 |
2021 |
-80.39 |
-31.36 |
What is the 52 Week High and Low of MoonLake Immunotherapeutics (MLTX)?
The 52-week high and low of MoonLake Immunotherapeutics (MLTX) are Rs 62.75 and Rs 5.95 as of 29-Aug-2026.
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics (MLTX) has a market capitalisation of $ 1,341 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MoonLake Immunotherapeutics (MLTX)?
Before investing in MoonLake Immunotherapeutics (MLTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.